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Dysregulation of the haem-haemopexin 
axis is associated with severe malaria  
in a case–control study of Ugandan children
Robyn E. Elphinstone1,2,3, Frank Riley4, Tian Lin4, Sarah Higgins1,2,3, Aggrey Dhabangi5, Charles Musoke5, 
Christine Cserti‑Gazdewich6, Raymond F. Regan7, H. Shaw Warren4† and Kevin C. Kain1,2,3*†
Abstract 
Background: Malaria is associated with haemolysis and the release of plasma haem. Plasma haem can cause 
endothelial injury and organ dysfunction, and is normally scavenged by haemopexin to limit toxicity. It was hypoth‑
esized that dysregulation of the haem‑haemopexin pathway contributes to severe and fatal malaria infections.
Methods: Plasma levels of haemin (oxidized haem), haemopexin, haptoglobin, and haemoglobin were quantified in 
a case–control study of Ugandan children with Plasmodium falciparum malaria. Levels at presentation were compared 
in children with uncomplicated malaria (UM; n = 29), severe malarial anaemia (SMA; n = 27) or cerebral malaria (CM; 
n = 31), and evaluated for utility in predicting fatal (n = 19) vs non‑fatal (n = 39) outcomes in severe disease. A causal 
role for haemopexin was assessed in a pre‑clinical model of experimental cerebral malaria (ECM), following disruption 
of mouse haemopexin gene (hpx). Analysis was done using Kruskall Wallis tests, Mann–Whitney tests, log‑rank tests for 
survival, and repeated measures ANOVA.
Results: In Ugandan children presenting with P. falciparum malaria, haemin levels were higher and haemopexin 
levels were lower in SMA and CM compared to children with UM (haemin, p < 0.01; haemopexin, p < 0.0001). Among 
all cases of severe malaria, elevated levels of haemin and cell‑free haemoglobin at presentation were associated 
with subsequent mortality (p < 0.05). Compared to ECM‑resistant BALB/c mice, susceptible C57BL/6 mice had lower 
circulating levels of haemopexin (p < 0.01), and targeted deletion of the haemopexin gene, hpx, resulted in increased 
mortality compared to their wild type littermates (p < 0.05).
Conclusions: These data indicate that plasma levels of haemin and haemopexin measured at presentation correlate 
with malaria severity and levels of haemin and cell‑free haemoglobin predict outcome in paediatric severe malaria. 
Mechanistic studies in the ECM model support a causal role for the haem‑haemopexin axis in ECM pathobiology.
Keywords: Severe malaria, Cerebral malaria, Severe malarial anaemia, Haemopexin, Haptoglobin, Haem, 
Haemoglobin, Experimental cerebral malaria
© 2015 Elphinstone et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Severe malaria (SM), including severe malarial anaemia 
(SMA) and cerebral malaria (CM), is associated with 
high fatality rates [1, 2]. Although the pathogenesis of SM 
remains unclear, fatal disease is associated with increased 
parasite burdens, excessive inflammation, endothelial 
activation, and multi-organ dysfunction [1–3]. During 
malaria infection there is haemolysis of both parasitized 
and non-parasitized erythrocytes causing the release of 
cell-free haemoglobin. Cell-free haemoglobin is read-
ily oxidized to methaemoglobin which releases plasma 
haem. Plasma haem is toxic to vascular endothelium via 
a number of established mechanisms, including iron-
mediated oxidative stress, increased complement activa-
tion [4], induction of pro-inflammatory mediators [5], 
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exocytosis of Weibel-Palade bodies [4, 6], increased leu-
kocyte and platelet adhesion [6], and cell death [7]. Under 
normal physiological states, cell-free haemoglobin and 
haem are promptly bound by circulating haptoglobin 
and haemopexin, respectively, leading to their inactiva-
tion via various pathways, including by haem-oxygenase 
1 [8]. However, in conditions of intravascular haemolysis 
these protective pathways may be overwhelmed resulting 
in oxidative stress, reduced nitric oxide bioavailability, 
inflammation, endothelial activation, and platelet/fibrin 
microthrombi that together culminate in vascular dys-
function and multi-organ injury.
Malaria causes haemolysis, however the key compo-
nents of the haem axis, specifically haemopexin and its 
role, have not been well studied in SM. This study tests 
the hypothesis that severe malarial syndromes are asso-
ciated with higher plasma haem and lower levels of hae-
mopexin and haptoglobin. Using a case–control study the 
association of the haem axis with severe and fatal malaria 
in African children was investigated. These investigations 
were extended to explore a potential mechanistic role for 
haemopexin using a pre-clinical animal model.
Methods
Study participants
This case–control study was nested within a large, 
observational, prospective study of febrile children 
(0.5–10.6  years) presenting with smear-confirmed Plas-
modium falciparum malaria to Mulago Hospital [9]. 
Mulago Hospital is the district hospital for Kampala, 
which is located in central Uganda, a region with mod-
erate or meso-endemicity. All study participants were 
local residents. Children were eligible for enrolment in 
this study if they met WHO criteria for SMA (Hb <5.0 g/
dL) or CM [BCS <3, either before or >6 h after seizures 
(or anticonvulsant medication), OR >3 seizures witnessed 
within a 24-hour period; and, absence of hypoglycemia 
(<2.2 mM), lumbar puncture evidence of bacterial men-
ingitis or intracranial haemorrhage or any known non-
malaria-related neurologic abnormalities which may 
alternatively explain coma] [10], or had uncomplicated 
malaria (UM) (Hb  >7.0  g/dL, platelet count >100,000/
uL, with absence of hypoxia, lactic acidosis, respiratory 
distress, seizures, and coma); and, had a pre-treatment 
plasma sample collected at presentation and stored fro-
zen (without a freeze–thaw) until analysis. No children 
had a history of haemoglobinopathy. All of the children 
in this study were tested for haemoglobin S (HbS) using 
SickleDex® (Streck Laboratories, Omaha, NB, USA) 
(except n =  6). Children were excluded from the larger 
trial if they had severe malnutrition that necessitated 
transfer to the Nutrition Ward (based on clinical judge-
ment of the attending physician); or if they had a history 
of HIV/AIDS or a positive HIV ELISA test [9]. Children 
are routinely screened for HIV as part of their clinical 
care. Children were tested for HIV using a screening 
assay, and any positive tests were confirmed with a sec-
ond ELISA. All children were treated according to Ugan-
dan national malaria guidelines for the treatment of SM 
and standard operating procedures at Mulago Hospital 
[9]. This study was approved by the Mulago Hospital 
Research Ethics Committee, Makerere University, Fac-
ulty of Medicine Research Ethics Committee, Uganda 
National Council for Science & Technology, and the Uni-
versity Health Network. Written informed consent was 
provided by a parent/guardian prior to enrolment.
Plasma haem is readily oxidized to haemin, there-
fore, plasma haemin was measured using a colorimetric 
assay (BioVision, Milpitas, CA, USA). ELISA was used to 
measure concentrations of cell-free haemoglobin (Bethyl 
Laboratories, Montgomery, TX, USA), haemopexin and 
haptoglobin (GenWay Biotech, San Diego, CA, USA). 
The limits of detection were: haemin 0.5–600  µM; 
cell-free haemoglobin 22–16,000  µg/mL; haemopexin 
63–4000  µg/mL, and haptoglobin 2–2000  µg/mL. A 
standard curve was run for each assay with manufactur-
er’s standards, as well as normal human serum to confirm 
no assay-to-assay variation.
Experimental cerebral malaria (ECM)
Determining endogenous levels of haemopexin 
in ECM‑resistant and ‑susceptible mice
Wild type C57BL/6 mice (highly susceptible to ECM) 
and wild type BALB/c mice (moderately resistant to 
ECM) were purchased from Jackson Laboratories (Sac-
ramento, CA, USA). Female mice were used between 
eight and 12  weeks of age. Plasmodium berghei ANKA 
was obtained from MR4 (MRA-311) and cryopreserved 
stocks were passaged through mice prior to infec-
tion. Mice were infected intraperitoneally with 106 P. 
berghei  ANKA-infected erythrocytes. On the day of 
tissue collection (either day 6 or day 7 post infection, 
dependent on infection kinetics), heparinized plasma was 
collected via cardiac puncture.
Determining the susceptibility of haemopexin‑deficient mice
Haemopexin heterozygous mice were kindly pro-
vided by Dr Frank Berger (University of South Caro-
lina), and were originally derived from Tolosano et  al. 
[11]. These mice are on a mixed C57BL/6; 129S6/Sv 
background and heterozygous mice were bred. In all 
experiments, littermates, both males and females ages 
8–12  weeks, were used. Mice were infected with 105 
P. berghei  ANKA-infected erythrocytes injected intra-
peritoneally. The mice were followed daily for periph-
eral parasitaemia determined by thin blood smear. 
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Infected mice followed for survival were euthanized 
when moribund, which included signs of ECM, includ-
ing limb paralysis, seizures and coma, or a greater than 
20  % decrease in body weight. Plasma was collected 
from infected mice via saphenous vein bleeds or when 
moribund via cardiac puncture. Animal studies were 
reviewed and approved by the University Health Net-
work Animal Care Committee. Murine plasma was 
stored frozen at −80  °C until analysis. ELISAs were 
used to measure plasma levels of murine haptoglobin 
and murine haemopexin (Immunology Consultants 
Laboratory, Portland, OR, USA), and haemin was 
measured using a colorimetic assay (BioVision, Milpi-
tas, CA, USA). The limits of detection for the murine 
markers were: haemopexin 125–16,000 ug/mL, hapto-
globin 39–5000 ug/mL and haemin 0.2–8.4 uM.
Statistical analysis
Survival was analysed using the log-rank test; repeated 
measures ANOVA was used to compare levels of murine 
haemopexin or haptoglobin over time between geno-
types; non-parametric analyses was used to compare 
plasma levels, either Mann–Whitney tests or Kruskal–
Wallis analysis followed by Dunn’s Multiple Comparison 
tests. All statistical analyses were performed using Graph 
Pad Prism 6 or IBM SPSS Statistics Version 22.
Results
Children with severe malaria
This study included cases of SM, either CM (n = 31) or 
SMA (n =  27), and children with UM (n =  29) as con-
trols. Of the children with SM, there were 19 deaths and 
39 survivors. None of the children had sickle cell dis-
ease (HbSS), and six of the children had sickle cell trait 
(HbAS) (UM, n = 2; SMA, n = 2; CM, n = 2; including 
one death). Patient characteristics are shown in Table 1. 
At presentation children with SMA had 11-fold [median 
(IQR): 11.1 µM (2.4, 26.9), p < 0.01] and CM had 15-fold 
higher [15.8 (5.2, 30.6), p < 0.001] median plasma levels 
of haemin compared to children with UM [1.0 (0.5, 6.5); 
Fig. 1]. Children with UM had significantly higher levels 
of haemopexin [993 µg/mL (766, 1144)] than those with 
SMA [221 (63, 338); p < 0.0001] or CM [292 (106, 525); 
p  <  0.0001; Fig.  1]. Similarly, haptoglobin levels were 
significantly higher in patients with UM [109 µg/mL (6, 
1130)] compared to those with SMA (2 [2, 6]; p < 0.0001) 
or CM (7 [3, 17]; p < 0.05). Haptoglobin levels were sig-
nificantly lower in children with SMA compared to CM 
(p < 0.05; Fig. 1).
Since both children with CM or SMA showed similar 
evidence of dysregulation of the haem axis, the associa-
tion of haemin and cell-free haemoglobin levels with out-
come was then examined. Among children with SM (CM 
and SMA cases combined) plasma levels of both haemin 
[23.0 µM (6, 47.9) vs 8.4 (2.3, 20.30), p = 0.03] and cell-
free haemoglobin [734.0  µg/mL (196.0, 2255) vs 222.0 
(84.0, 669), p = 0.01] were significantly higher at presen-
tation in those who subsequently went on to die of their 
infection compared to children who survived (Fig.  2). 
Sub-group analysis of children with either CM or SMA 
showed similar trends with respect to levels of haemin 
and cell-free haemoglobin and an increased risk of fatal 
outcome but these did not reach statistical significance 
(Additional file 1: Figure S1).
Table 1 Descriptive characteristics of the patient population
Continuous variables analysed by Mann–Whitney, or Kruskall Wallis with Dunn’s multiple comparisons; categorical variable analysed by Chi square analysis
Median (IQR), uncomplicated malaria (UM), cerebral malaria (CM), severe malarial anaemia (SMA), severe malaria (SM)
Dunn’s multiple comparison tests: UM vs SMA * p < 0.05, *** p < 0.001; UM vs CM $$  p < 0.01, $$$ p < 0.001; CM vs SMA # p < 0.05, ## p < 0.01, ### p < 0.001
Combined SM (All children with SMA or CM)
Characteristic UM (n = 29) CM (n = 31) SMA (n = 27) P value Survivors (n = 39) Deaths (n = 19) P value
Gender (% female) 48.3 58.1 48.1 0.679 48.7 63.2 0.301
Age (years) 3.2 (2.1, 7.4)*** 3.1 (1.5, 4.4)## 1.3 (1.0, 2.2)##,*** 0.000 1.9 (1.0, 4.0) 2.1 (1.3, 3.4) 0.673
Days reported ill prior
to presentation
3 (2, 4)* 3 (2, 4)## 4 (3, 5)*,## 0.004 3 (3, 4) 3 (2, 5) 0.496
Parasitaemia  
(parasites/uL)
6.0 × 104 (9.9 ×103,  
1.4 × 105)
8.2 × 104 (1.8 × 104,  
2.8 × 105)
3.2 × 104 (5.3 × 103,  
1.4 × 105)
0.090 3.7 × 104  (6.2 × 103,  
1.4 × 105)
1.6 × 105 (1.8 × 104,  
4.4 × 105)
0.106
Red blood cell  
haemoglobin (g/dL)
10.0 (9.2, 11.3)***,$$ 7.1 (5.8, 9.3)###,$$ 3.8 (3.2, 4.6)###,*** 0.000 4.7 (3.5, 7.1) 5.4 (4.6, 8.3) 0.134
Platelet count (x109/L) 162 (104, 258)$$$ 67 (43, 128)$$$ 126 (86, 180) 0.001 95 (50, 174) 73 (41, 128) 0.230
Weight (kg) 14 (11, 22)*** 13 (10, 15)## 10 (7.5, 11)##,*** 0.000 10 (8, 14) 11 (10, 13) 0.269
Fatal cases (count) 0 13 6 0 19
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Excluding the children with the protective sickle cell 
trait (HbAS) from the analysis did not alter the associa-
tions of the haem axis markers. In summary, these data 
are consistent with the hypothesis that severe malarial 
syndromes are associated with changes in the haem axis.
Experimental cerebral malaria
BALB/c mice infected with P. berghei ANKA had signifi-
cantly improved survival compared to the C57BL/6 mice 
(40  % survival vs 0  %, p =  0.003) with similar levels of 
parasitaemia during the course of infection (Fig.  3a, b). 
When the susceptible mice were exhibiting signs of ECM 
(day 6 or day 7 post infection), the plasma levels of hae-
mopexin were significantly higher in BALB/c mice com-
pared to the more susceptible C57BL/6 mice [4185 ug/
mL (3557, 4550) vs 3080 ug/mL (1814, 3472), p = 0.005; 
Fig.  3d]. Furthermore, mice with targeted disruption of 
the hpx gene had significantly decreased survival com-
pared to their wild type littermates (10 vs 38 % survival, 
p = 0.022; Fig. 4a). This was associated with significantly 
higher levels of plasma haemin at day 7 post infection 
in the haemopexin knockout animals compared to the 
wild type animals [>8.4 uM (7.3, 8.4) vs 3.6 (3.2, 5.6), 
p =  0.005; Fig.  4c]. The haemopexin heterozygous mice 
had approximately half the circulating levels of hae-
mopexin than their wild-type counterparts throughout 
the course of infection (Fig.  4d) but responded more 
similarly to the haemopexin-null mice. There was a 
trend towards a difference in survival between the hae-
mopexin heterozygous mice compared to their wild-type 
littermates but it did not reach statistical significance (18 
vs 38 % survival, p = 0.068; Fig. 4a). There were no dif-
ferences observed in peripheral parasitaemia (Fig.  4b) 
or weight loss between the genotypes. Haemopexin 
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Fig. 1 Alterations of the haem axis are associated with disease severity in children with malaria. Plasma samples were collected at presentation. 
Higher plasma levels of haemin, an oxidized form of haem, and lower levels of haemopexin and haptoglobin were associated with SMA and 
CM in Ugandan children compared to children with UM. Kruskal–Wallis Test followed by Dunn’s Multiple Comparison Test, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001
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knockout animals and their wild-type counterparts suc-
cumb to ECM during the ECM window (days 6–10); 
these mice begin to die roughly 2 days later than the 
C57BL/6 mice due to a lower inoculum (105 vs 106 para-
sitized erythrocytes, respectively). The mice that survived 
this period succumbed to anaemia/hyperparasitaemia 
and/or had to be euthanized due to weight loss (>20 %).
In response to acute haemolysis, haemopexin-deficient 
mice increase their plasma levels of haptoglobin to a 
greater degree than their heterozygous or wild-type lit-
termates throughout the course of infection (p = 0.0002; 
Fig.  4e). Mice deficient in haemopexin displayed higher 
median levels of haptoglobin at baseline prior to infec-
tion (89 ug/mL compared to undetectable) compared to 
their wild-type counterparts. Following infection, hap-
toglobin levels in the haemopexin-null mice reached a 
peak at day 7 post infection with a median of 1324 ug/mL 
while the levels in both the haemopexin wild type and 
haemopexin heterozygous mice remained undetectable. 
When the mice were moribund, the haptoglobin levels in 
the haemopexin-deficient mice had dropped to a median 
of 783 ug/mL, while the other genotypes continued to 
have undetectable levels of haptoglobin. Together, these 
data are consistent with the hypothesis that haemopexin 
is playing a mechanistic role during ECM.
Discussion
SM is a complex, multi-organ syndrome that is poorly 
understood. This study provides evidence that increased 
generation of plasma haem, combined with lower lev-
els of haemopexin that normally binds and clears haem, 
are associated with both SMA and CM in Ugandan 
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Fig. 2 Plasma levels of haemin and cell‑free haemoglobin are associated with disease outcome in severe malaria. Children who died of SM, either 
SMA or CM, had higher plasma levels of haemin and cell‑free haemoglobin at presentation compared to children who survived SM. Levels of hae‑
mopexin and haptoglobin were lower than those observed in children with UM but were not significantly different between those who survived 
SM and those who did not. The dotted lines indicate the median levels observed in children with UM. Mann–Whitney test, *p < 0.05
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children. Furthermore, decreased or depleted levels of 
haemopexin, and increased plasma haem, are associated 
with a worse outcome in a pre-clinical model of CM. 
These observations support the hypothesis that haem-
induced pathology, exacerbated by decreased levels of 
haemopexin, may be a pathway of injury contributing to 
disease severity and death in malaria infections.
The observed median plasma levels of haemin in chil-
dren with CM and SMA were ten-fold or higher than that 
observed in UM [12], and equivalent to those reported 
in haemolytic disorders such as sickle cell disease [4], 
where haem-induced vasculopathy is a frequent cause of 
organ dysfunction and mortality [8]. Although there were 
no differences in cell-free haemoglobin levels between 
groups, given the 11–15-fold higher levels of plasma hae-
min observed in children with SMA and CM and that 
cell-free haemoglobin generates haem, it is likely that 
there were also differences in levels of plasma haemoglo-
bin during the course of infection, but the timing of sam-
ple collection did not capture these events.
Previously it has been shown that plasma levels of haem 
are higher on day 6 post infection in the ECM-susceptible 
C57BL/6 mice compared to ECM-resistant BALB/c mice 
[13]. Injections of haemin into resistant BALB/c mice 
infected with P. berghei ANKA resulted in increased 
fatalities compared to controls (100 vs 0 %) [13, 14], sug-
gesting that haem may play an important role in mediat-
ing, or enhancing, disease severity. While a role for haem 
has previously been implicated in ECM, it had yet to be 
confirmed in informative human populations. Recently, 
Dalko et al. showed that adults with SM in India had ele-
vated levels of plasma haem compared to those with mild 
malaria, which were both higher than levels measured 
in endemic controls [15]. These findings were extended 
in this study to show an association between increased 
haem and disease severity in African children with SM 
compared to those with UM.
It is hypothesized that haem is mediating adverse out-
comes during malaria infection by inducing endothelial 
dysfunction and microvascular injury. Haem is impli-
cated, directly or indirectly, as a key mediator of endothe-
lial dysfunction by a variety of pathways. Plasma haem 
is a major source of reactive oxygen species (ROS) and 
subsequent pro-oxidant stress on endothelium [8]. Haem 
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Fig. 3 Endogenous levels of haemopexin are associated with susceptibility to experimental cerebral malaria. a BALB/c mice are more resistant to 
ECM than C57BL/6 mice as demonstrated by improved survival (pooled data from two biological replicates; n = 15–17 per group; log rank test, 
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also induces activation of the endothelium by: inducing 
Weibel-Palade body exocytosis and the release of their 
contents, including the release of von Willebrand fac-
tor (vWF), p-selectin [4, 6], and Ang-2, and increasing 
expression of endothelial adhesion markers that bind 
both inflammatory cells and parasitized erythrocytes 
[6]. Haem is also a pro-inflammatory molecule that can 
stimulate complement activation [4] and the release 
of pro-inflammatory cytokines from monocytes/mac-
rophages [16]. Haem-induced endothelial injury may be 
further exacerbated by decreases in bioavailable nitric 
oxide. Cell-free haemoglobin in addition to generating 
plasma haem, is a potent scavenger of nitric oxide, fur-
ther amplifying endothelial dysfunction [8, 17]. Many of 
these pathways induced by haem are also implicated in 
the pathogenesis of SM [3, 17–23]. Further prospective 
studies are required to define which of the above path-
ways are induced by haem in the context of SM.
The toxic effects of cell-free haemoglobin and haem 
are normally mitigated by high affinity-binding to hap-
toglobin and haemopexin, respectively, followed by 
transport and degradation. Haem is degraded by haem 
oxygenase-1 resulting in the generation of biliverdin and 
carbon monoxide which have anti-inflammatory and 
endothelial stabilizing effects [8]. Therefore, the excess 
generation of haemin observed in children with CM and 
SMA appears to be further complicated by a relative defi-
ciency in circulating haemopexin. Previous studies have 
primarily focused on levels of haptoglobin [12, 24–26] 
or haemopexin [24–26] in UM. However, it was recently 
shown that adults with SM in India had decreased levels 
of haemopexin compared to those with mild malaria [15]. 
Similarly, in this study it was observed that children with 
SMA had significantly lower levels of both haemopexin 
and haptoglobin, in agreement with a previous report 
[25]. This study extends these previous findings and 
reports that African children with CM also have lower 
levels of both haemopexin and haptoglobin, suggesting 
a common pathway of endothelial injury in both CM 
and SMA, and in both adults and children with severe 
disease. Despite the markedly low levels of these protec-
tive proteins in children with CM or SMA, there were 
no observed differences in either haemopexin or hap-
toglobin levels between children who survived or died 
of the infection. These data suggest that these proteins 
are already depleted during severe infection. Whether 
these relative deficiencies are due to consumption or due 
to a decreased capacity to synthesize these proteins in 
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response to haemolysis is unknown. Nonetheless, these 
low levels would be expected to further compromise 
clearance and degradation of haem and haemoglobin, 
and contribute to worse clinical outcomes, as was illus-
trated by the observed higher plasma levels of haemin 
and cell-free haemoglobin in children who subsequently 
died of malaria.
Due to the associations observed in children with CM 
or SMA, a potential mechanistic role for haemopexin 
was investigated using a pre-clinical model of ECM. As 
with all animal models, there are inherent limitations. 
However, there is evidence that this model shares sev-
eral features, but not all, with human malaria [27–32]. 
Pre-clinical models enable investigation of mechanistic 
questions that are difficult to safely or ethically address 
in human populations and can provide direct genetic evi-
dence that the haem axis is causally involved in severe 
and fatal infection.
Similar to this patient population, mice that were more 
susceptible to ECM had significantly lower haemopexin 
levels compared to more resistant mice, despite compa-
rable parasite burdens. Furthermore, mice with targeted 
deletion of the hpx gene, and no measurable circulat-
ing haemopexin, were more susceptible to ECM than 
their wild-type littermates suggesting that haemopexin is 
playing a mechanistic role during malaria infection. The 
increased susceptibility in the Hpx KO animals was asso-
ciated with increased levels of plasma haemin prior to the 
onset of ECM, further implicating a role for plasma haem.
A dose response to ECM was predicted due to the gene 
dosing effect observed in these mice; however, both the 
haemopexin-null and heterozygous mice responded sim-
ilarly to ECM. The haemopexin-null mice appear to com-
pensate for their lack of haemopexin by increasing the 
production of haptoglobin. The haemopexin-null mice 
have higher baseline levels of haptoglobin compared to 
both the wild type and heterozygous mice. When infected 
with P. berghei ANKA, haemopexin-deficient mice fur-
ther upregulate circulating haptoglobin to at least 1300 
times the levels seen in either the wild type or heterozy-
gous mice. This compensation in a protein upstream of 
haemopexin in the haemolytic pathway is hypothesized 
to mitigate the severity of the observed phenotype. The 
haemopexin heterozygous mice may more accurately 
reflect the impact of haemopexin deficiency in ECM due 
to their inability to compensate with increased levels of 
haptoglobin to the levels observed in haemopexin-null 
mice. It would be of interest to further explore the phe-
notype of a double haemopexin, haptoglobin knockout 
mouse in the ECM model.
Despite the marked increase in haptoglobin, hae-
mopexin-null mice are still more susceptible than their 
wild-type counterparts. This is likely attributable to 
malaria-induced generation of plasma haemoglobin and 
haem that overwhelms both haptoglobin and/or hae-
mopexin pathways, as demonstrated by significantly 
higher levels of plasma haem prior to the onset of ECM 
in the KO animals. Alternatively, haemopexin may pro-
vide additional protection independent of its ability to 
clear haem from the circulation. Haemopexin has been 
shown to exert haem-independent, anti-inflammatory 
effects by decreasing the release of pro-inflammatory 
cytokines from lipopolysaccharide (LPS) stimulated mac-
rophages [33], and decreased differentiation of TH17 
cells in a model of experimental autoimmune encephali-
tis [34].
Collectively, the above observations suggest that 
malaria-induced haem, and corresponding haemopexin 
deficiency may represent a component of disease patho-
genesis in which haem amplifies complement activation, 
pro-coagulant activity and endothelial injury, culminating 
in microangiopathy, multi-organ dysfunction and adverse 
clinical outcomes. The recent observation that both cases 
of CM and SMA are associated with parasitized erythro-
cytes that bind to endothelial protein C receptor (EPCR) 
lends further support to this hypothesis [35]. Binding to 
EPCR may disrupt the anti-inflammatory and endothe-
lial barrier effects of activated protein C (APC), resulting 
in enhanced pro-coagulant activity, complement activa-
tion and endothelial injury. Of note, APC mediates its 
endothelial cytoprotective and barrier protective activi-
ties via the Ang-Tie2 pathway [36], which is dysregu-
lated in SM [37]. Moreover, since parasitized erythrocyte 
sequestration focuses parasite burdens and erythrocyte 
haemolysis directly onto the microvasculature of vital 
organs, this would be expected to result in higher local 
haem concentrations in the cerebral microvascular bed, 
than those observed in the peripheral circulation.
Similar to atypical haemolytic uremic syndrome 
(aHUS) associated with infection, where haem-induced 
complement activation is a proposed common pathway 
of microvascular injury and organ failure, severe disease 
does not occur in all infected individuals, but rather only 
in those with genetic or acquired defects in complement 
regulation [4]. This suggests that similar or related sus-
ceptibility determinants, including defects in haemopexin 
expression or haem metabolism, may contribute to the 
onset and outcome of severe malarial syndromes.
Conclusions
These data support the hypothesis that elevated plasma 
haem contributes to the pathobiology of severe and 
fatal malaria. Future studies will need to confirm these 
findings and investigate other potential interactions 
(e.g., Ang-Tie2 axis) contributing to haem axis dysfunc-
tion in children with severe malarial syndromes. The 
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identification of plasma haem as a potential mediator 
of disease pathogenesis suggests potential therapeutic 
interventions, including the administration of exogenous 
haemopexin which has been shown to confer protection 
to haem-induced endothelial injury in models of chronic 
haemolysis [8], and in models of sepsis [7].
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